18F Suberoylanilide Hydroxamic Acid,
18F-SAHA,
18F-suberoylanilide hydroxamic acid,
M344,
MK 0683,
MK-0683,
MK0683,
N Hydroxy N' phenyloctanediamide,
N-hydroxy-N'-phenyloctanediamide,
N1 Hydroxy N8 phenyloctanediamide,
N1-hydroxy-N8-phenyloctanediamide,
NHNPODA,
suberanilohydroxamic acid,
suberoyl anilide hydroxamic acid,
suberoylanilide hydroxamic acid,
Vorinostat,
zolinza,
m344,
251456-60-7,
M 344,
4-(dimethylamino)-n-[7-(hydroxyamino)-7-oxoheptyl]benzamide,
Histone Deacetylase Inhibitor III,
N-Hydroxy-7-(4-dimethylaminobenzoyl)aminoheptanamide,
4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide,
CHEMBL140000,
M-344,
4-Dimethylamino-N-(6-hydroxycarbamoylhexyl)benzamide,
MFCD03453554,
MS 344,
MS 344, D237,
4-(Dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-benzamide,
Benzamide, 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-,
N-Hydroxy-7-(4-dimethylaminobenzoyl)-aminoheptanamide,
AC1L1H6E,
AC1Q5QD9,
M 344 (Enzyme Inhibitor),
MLS006011092,
SCHEMBL675763,
CTK8F1321,
KS-00000XGZ,
DTXSID90274415,
CHEBI:125562,
HMS3648E20,
HMS3656B08,
3802AH,
BDBM50082665,
IN1469,
NSC718169,
s2779,
ZINC12502280,
AKOS022183358,
CCG-208693,
CS-1342,
DB02565,
NSC-718169,
VZ27896,
M344, >=98% (HPLC), powder,
NCGC00263617-05,
AJ-62447,
AK-78558,
D237,
HY-13506,
NCI60_040738,
SC-94509,
SMR004702880,
AB0048276,
RT-013641,
D4188,
FT-0669552,
ST24043087,
SW219379-1,
EC-000.2275,
W-5303,
456M607,
SR-01000946361,
J-015838,
SR-01000946361-1,
BRD-K45528773-001-02-3,
BRD-K45528773-001-03-1,
4-Dimethylamino-N-(6-hydroxycarbamoyl-hexyl)-benzamide,
4-(diethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide,
4-DIMETHYLAMINO-N-(6-HYDROXYCARBAMOYLHEXYL)-BENZAMIDE,
Benzamide,4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-,
CID3994,
C16H25N3O3,
AR-1F6934,
D 237,
A11355,
25648-84-4,
4-DIMETHYLAMINO-N-(6-HYDROXYCARBAMOYETHYL)BENZAMIDE-N-HYDROXY-7-(4-DIMETHYLA MINOBENZOYL)AMINOHEPTANAMIDE,
B3N,